J

Johnson & Johnson

Makes prescription drugs and medical devices

Transcend Deployment Logistics Manager

Full-TimePosted on 10/19/2026Deadline 10/28/26
€56.1k - €121.2k+ Annual target bonus
Senior
Bachelor's, Master's
Loughbeg, Ringaskiddy, Co. Cork, Ireland+2 moreMore locations: Leiden, Netherlands | Latina, Italy
Hybrid
Project & Program ManagementProgram Management

About the job

Requirements
  • A bachelor's degree in Supply Chain, Engineering, Business, Information Systems, Logistics, or a related field is required.
  • A minimum of 6 years of experience in Supply Chain, Logistics, ERP Deployment, Operations, or Program Management is required.
  • Experience implementing enterprise systems such as SAP ECC, SAP S/4HANA, Oracle, or equivalent ERP platforms is required.
  • Experience leading cross-functional projects in a complex, global environment is required.
  • Strong understanding of logistics, warehousing, transportation, and inventory management processes is required.
  • Experience working with third-party logistics providers is required.
  • The role requires strong program leadership, stakeholder management, and supply chain expertise.
  • The successful candidate should demonstrate an enterprise mindset and strategic thinking, ability to influence across all levels of the organization, communication and stakeholder management skills, data-driven decision making, a continuous improvement mindset, ability to navigate ambiguity and drive results, and collaboration and team leadership capabilities.
  • The candidate should be able to translate complex technical concepts into business outcomes and have proven success delivering results in matrixed environments.
Responsibilities
  • Lead logistics deployment activities for Transcend program releases and site implementations.
  • Partner with global process owners and deployment teams to execute best-practice deployment strategies and timelines.
  • Drive logistics workstream readiness assessments and risk mitigation plans.
  • Ensure alignment between business requirements and standardized global solutions.
  • Support end-to-end logistics processes, including inventory management, warehouse management operations, shop floor inventory management, transportation management, distribution and fulfillment, third-party logistics integration (including off-site storage sites and vendor-managed inventory), batch traceability and serialization, goods receipt, internal goods movements, and goods issue processes.
  • Facilitate fit-gap discussions and deployment decisions with business stakeholders.
  • Coordinate business simulation testing, user acceptance testing, training, and cutover activities.
  • Ensure business users are prepared to adopt new processes and technologies.
  • Develop deployment communications and executive status reporting.
  • Manage stakeholder expectations and drive issue resolution.
  • Partner with Manufacturing, Planning, Procurement, Quality, Finance, and IT organizations.
  • Collaborate with external logistics providers and integration partners.
  • Support master data readiness and data governance activities.
  • Identify process improvement opportunities that enhance service, efficiency, and compliance.
  • Track deployment risks, issues, dependencies, and mitigation plans.
  • Present deployment readiness updates to leadership teams and governance forums.
  • Monitor deployment KPIs and stabilization activities after go-live.
  • Ensure adherence to compliance, quality, and validation requirements.
Desired Qualifications
  • A master's degree is preferred.
  • Experience supporting global ERP transformation programs is preferred.
  • Knowledge of healthcare, pharmaceutical, medical device, or regulated industries is preferred.
  • Experience with deployment methodologies, cutover planning, and change management is preferred.
  • Familiarity with master data management and systems integration is preferred.
  • Project Management Professional (PMP), Agile, Lean, or Six Sigma certification is preferred.
  • SAP HANA S/4 transactional and table knowledge is preferred.
  • Familiarity with IM/GL and data migration processes is preferred.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

6 month growth

6%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 22nd, 2026
JNJ rated buy with $289 target as pharma growth of 8% outpaces MedTech's 2.5%

Johnson & Johnson (JNJ) earns a "buy" rating from 24/7 Wall St., with a 12-month price target of $288.66. That implies 11.48% upside from the $258.93 close on October 20. Growth is coming from pharma. Innovative Medicine sales rose 7.9% last quarter, while MedTech grew 2.5%. The analyst says the stock hinges on whether devices can close that gap. Third-quarter sales reached $25.4 billion. Adjusted earnings per share (EPS) were $2.59, but GAAP EPS fell to $0.09 after about $7 billion of charges, mostly tied to a proposed talc settlement and two deals. Management cut adjusted EPS guidance to $11.05 to $11.15. The bull case is $302.93, or 17% upside. Tremfya grew 68%, and management expects it to become a $10 billion-plus franchise.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.